Molecular Biology Program
The Simon Powell Lab
Moore, G. et al. Templated Insertions Are Associated Specifically with BRCA2 Deficiency and Overall Survival in Advanced Ovarian Cancer. Mol. Cancer Res. 20, 1061–1070 (2022)
Anand, R. et al. HELQ is a dual-function DSB repair enzyme modulated by RPA and RAD51. Nature 601, 268–273 (2022)
Setton, J., Reis-Filho, J. S. & Powell, S. N. Homologous recombination deficiency: how genomic signatures are generated. Curr. Opin. Genet. Dev. 66, 93–100 (2021). Review.
Setton, Zinda, Riaz, Durocher & Zimmermann. Synthetic Lethality in Cancer Therapeutics: The Next Generation Cancer Discov. (2021). Review
Samstein, R. M. et al. Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nat Cancer 1, 1188–1203 (2021)
Simon N. Powell, MD, PhD
- Molecular biologist Simon Powell investigates DNA replication and recombination, chromosome dynamics, and human genetics.
- PhD, MD, University of London
To learn more about available postdoctoral opportunities, please visit our Career Center
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Simon N. Powell discloses the following relationships and financial interests:
PharmaPier US LLC
Provision of Services (uncompensated)
Rain Therapeutics Inc.
Provision of Services
Varian Medical Systems
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.